ESMO - Eur. Oncology· @myESMO · X·· 1 天前评分70
正文 · 原文
#ESMO26: Neoadjuvant enfortumab vedotin significantly improved event-free and overall survival when added to peri-operative durvalumab for muscle-invasive #BladderCancer (#MIBC) in the phase III VOLGA #ClinicalTrial
🔗 https://ow.ly/8zVg50ZZl8e
#InsightsbyESMO #ADC
137 浏览 · 1 赞 · 0 转发 · 0 回复
会议摘要
LBA2按 Presidential Symposium I 对上
Perioperative durvalumab with or without tremelimumab plus neoadjuvant enfortumab vedotin in muscle-invasive bladder cancer: Results from the phase 3 VOLGA trial
https://esmocongress.esmo.orgVOLGA
https://esmocongress.esmo.org来源：ESMO - Eur. Oncology · x.com